24 July 2014
EMA/CHMP/413428/2014
Procedure Management and Business Support Division

Committee for medicinal products for human use (CHMP)

Final Minutes of meeting held on 23-26 June 2014

Chair: Tomas Salmonson – Vice-chair: Pierre Demolis

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents under Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regards to therapeutic indications listed against products it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. The procedures discussed by the CHMP are on-going and therefore certain aspects of them are considered confidential. Additional details on some of these procedures is published in the CHMP meeting highlights once the procedures are finalised and start of referrals are also available. For orphan medicinal products and products that received an opinion at this meeting, the applicant details are published as this information is already publicly available. The same applies for the product name for products that received an opinion at this meeting. Documents mentioned in these minutes cannot be released at present as they are currently in draft format or are classified as confidential. They will become public when adopted in their final form or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Of note, this set of minutes is a working document primarily designed for CHMP members and the work the Committee undertakes.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Further information with relevant explanatory notes can be found at the end of this document.

AGENDA (EMA/CHMP/312497/2014) and Annex to CHMP agenda of the CHMP plenary session to be held 23-26 June 2014	The agenda and annex were adopted with amendments.
TIMESCHEDULE of the CHMP plenary session to be held 23-26 June 2014	The timeschedule was adopted.
MINUTES of the CHMP plenary session held 19-22 May 2014(EMA/CHMP/329259/2014)	The Minutes of the CHMP plenary session held 19-22 May 2014 were adopted.
MINUTES of the June 2014 CHMP ORGAM meeting held on 16 June 2014 (EMA/CHMP/359130/2014)	The Minutes of the June 2014 CHMP ORGAM meeting held on 16 June 2014 were adopted together with all decisions taken at that meeting.
PRE-MEETING LIST of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 23-26 June 2014.	See June 2014 minutes (to be published post July 2014 CHMP meeting) The pre-meeting list was noted.
CONFLICT OF INTERESTS	In accordance with the Agency's revised policy and procedure on the handling of conflicts of interests, participants in this meeting were asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests). Discussions, deliberations and voting took place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee Secretariat at the start of meeting (see end of document). All decisions taken at this meeting were made in presence of a quorum of members – i.e. 22 or more members were present in the room.
Draft Agenda of July 2014 CHMP meeting	The draft agenda was noted.

Table of Contents

1. ORAL EXPLANATIONS

1.1. Pre-authorisation Procedure Oral Explanations

(EMEA/H/C/002314), (bazedoxifene / estrogens conjugated), (treatment of oestrogen deficiency and osteoporosis)
List of Outstanding Issues adopted in March 2014. List of Questions adopted in November 2012.
An Oral Explanation was held on Tuesday 24 June 2014 at 9.00.
See also 2.2 Day 180 List of Outstanding Issues

(EMEA/H/C/002418), Orphan (dexamethasone acetate), (treatment of symptomatic multiple myeloma)
List of Outstanding Issues adopted in September 2013 and February and April 2014. List of Questions adopted in May 2013.The CHMP was reminded of major outstanding issues on the quality part of the dossier, which were considered not to be solvable in the near future.
An oral explanation was held on Tuesday 24 June 2014 at 11.30. During the oral explanation the applicant addressed the quality issues. Doubts were expressed that the missing data can be provided in the requested time.
The CHMP did not accept the request by the applicant for an extension to the clock stop.

(EMEA/H/C/002647), (insulin degludec / liraglutide), (treatment of type 2 diabetes mellitus)
List of Outstanding Issues adopted on 20.03.2014. List of Questions adopted on 24.10.2013.
The Committee noted the report from the SAG Diabetes/ Endocrinology meeting held on 5 June 2014 where the SAG had expressed a split view on the issues raised.
An Oral Explanation was held on Tuesday 24 June 2014 at 14.45.
See section 2.2 List of Outstanding Issues

1.2. Re-examination Procedure Oral Explanation

No items

1.3. Post-authorisation Procedure Oral explanation

Ozurdex (EMEA/H/C/001140/II/0015), (dexamethasone), MAH: Allergan Pharmaceuticals Ireland, Rapporteur: Greg Markey, Co-Rapporteur: Concepcion Prieto Yerro, PRAC Rapporteur: Julie Williams, “Update of section 4.1 of the SmPC to add a new indication for treatment of adult patients with diabetic macular oedema.
The MAH also used this opportunity to implement QRD version 9.0.”
Request for Supplementary Information adopted on 20.02.2014, 24.10.2013.
An Oral Explanation was held on Wednesday 25 June 2014 at 9.00.
See also 4.1 Opinions or Requests for Supplementary information – Type II variation; Extension of indication

1.4. Community Procedure Oral Explanations

No items

2. NEW APPLICATIONS

2.1. Opinions – New full applications

Abasria (EMEA/H/C/002835) (insulin glargine), Applicant: Eli Lilly Regional Operations GmbH, (treatment of diabetes mellitus)
Similar biological application (Article 10(4) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 20.03.2014. List of Questions adopted on 10.10.2013.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The CHMP noted the letter of undertaking dated 19 June 2014.
The summary of opinion was circulated for information.
The Committee adopted the BWP report.

Clopidogrel/Acetylsalicylic acid Teva (EMEA/H/C/002272), (clopidogrel / acetylsalicylic acid), Applicant: Teva Pharma B.V., (indicated for the prevention of atherothrombotic events).
Fixed combination application (Article 10b of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 25.04.2014. List of Questions adopted on 18.12.2013.The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The summary of opinion was circulated for information.

Daklinza (EMEA/H/C/003768) (daclatasvir), Applicant: Bristol-Myers Squibb Pharma EEIG, (treatment of chronic hepatitis C virus treatment of chronic hepatitis C virus (HCV))
New active substance (Article 8(3) of Directive No 2001/83/EC). List of Questions adopted on 25.04.2014.
Accelerated review.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that daclatasvir is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as restricted medicinal product subject to medical prescription.
The summary of opinion was circulated for information.

Triumeq (EMEA/H/C/002754), (dolutegravir / abacavir / lamivudine), Applicant: ViiV Healthcare Uk Limited, (treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age who are antiretroviral treatment-naïve or are infected with HIV without documented or clinically suspected resistance to any of the three antiretroviral agents in Triumeq)
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Questions adopted on 20.03.2014.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
Furthermore, the CHMP considered that dolutegravir was to be qualified as new active substance at the time of submission of this application.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.

Velphoro (EMEA/H/C/002705), (mixture of polynuclear iron(iii)-oxyhydroxide, sucrose and starches), Applicant: Vifor Fresenius Medical Care Renal Pharma France, (is indicated for the control of serum phosphorus levels in patients with end-stage renaldisease (ESRD))
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 24.10.2013, 22.05.2014. List of Questions adopted on 30.05.2013.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that mixture of polynuclear iron(III)-oxyhydroxide, sucrose, and starches is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The summary of opinion was circulated for information.

VIZAMYL (EMEA/H/C/002557), (flutemetamol (18f)), Applicant: GE Healthcare Ltd, (indicated for the visual detection of amyloid-beta neuritic plaques in the brains)
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 19.12.2013. List of Questions adopted on 25.04.2013.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that flutemetamol (18F) is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The CHMP noted the letter of recommendation dated 25 June 2014.
The summary of opinion was circulated for information.

2.2. Day 180 List of outstanding issues – New full applications

(EMEA/H/C/002829), Orphan, (ramucirumab), Applicant: Eli Lilly Nederland B.V., (Treatment of gastric cancer)
List of Questions adopted on 23.01.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a List of Outstanding Issues with a specific timetable.
The Committee adopted the BWP report.

(EMEA/H/C/002314), (bazedoxifene / estrogens conjugated), (treatment of oestrogen deficiency and osteoporosis)
List of Outstanding Issues adopted in March 2014. List of Questions adopted in November 2012.See also 1.1 Pre-authorisation Procedure Oral Explanations
The CHMP noted the remaining issues for this application.
An Oral Explanation was held on Tuesday 24 June 2014 at 9.00.
The Committee adopted a 2nd List of Outstanding Issues with a specific timetable.

(EMEA/H/C/003791), Orphan, (ibrutinib), Applicant: Janssen-Cilag International NV (treatment of mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma)
List of Questions adopted on 20.03.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a List of Outstanding Issues with a specific timetable.

(EMEA/H/C/002810), (naloxegol), (Tradename is indicated for the treatment of adult patients 18 years and older with opioid-induced constipation (OIC) including patients with inadequate response to laxatives.)
List of Questions adopted on 23.01.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a List of Outstanding Issues with a specific timetable.

(EMEA/H/C/003726), Orphan, (olaparib), Applicant: AstraZeneca AB (treatment of ovarian cancer.)
List of Questions adopted on 23.01.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a List of Outstanding Issues with a specific timetable.
Furthermore the CHMP agreed on the need for a SAG and adopted a List of Questions to the SAG Oncology.

(EMEA/H/C/002819), (darunavir / cobicistat), (The treatment of patients with human immunodeficiency virus (HIV-1) in
• antiretroviral therapy (ART) naïve adults.
• ART-experienced adults with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ⩾ 100 cells x 106/l.)
List of Questions adopted on 20.02.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a List of Outstanding Issues with a specific timetable.

(EMEA/H/C/002825), (dulaglutide), (treatment of adults with type 2 diabetes mellitus)
List of Questions adopted on 20.02.2014.
The Committee was reminded of the status of this application and its remaining outstanding issues
The Committee adopted a List of Outstanding Issues with a specific timetable.
The Committee adopted the BWP report.
(EMEA/H/C/003843), (idelalisib), (Treatment of patients with relapsed chronic lymphocytic leukaemia (CLL) and refractory indolent non-Hodgkin lymphoma (iNHL).)
List of Questions adopted on 20.03.2014.
The members noted the List of experts for the SAG Oncology which was adopted via written procedure on 9 June 2014.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The CHMP noted the report from the SAG Oncology held on 10 June 2014.
The Committee adopted a List of Outstanding Issues with a specific timetable.

(EMEA/H/C/002647), (insulin degludec / liraglutide), (treatment of type 2 diabetes mellitus)
List of Outstanding Issues adopted on 20.03.2014. List of Questions adopted on 24.10.2013.
See also section I Oral explanations
The Committee noted the report from the SAG Diabetes/ Endocrinology meeting held on 5 June 2014.
An Oral Explanation was held on Tuesday 24 June 2014 at 14.45.
The Committee adopted a List of Outstanding Issues with a specific timetable.
The Committee adopted the BWP report.

2.3. Day 120 List of questions – New full applications

(EMEA/H/C/003906), Orphan, (ketoconazole), Applicant: Laboratoire HRA Pharma, (treatment of Cushing's syndrome)
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

(EMEA/H/C/002629), (edoxaban), (Prevention of stroke and systemic embolism and treatment of venous thromboembolism)
The Committee discussed the issues identified in this application
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

(EMEA/H/C/002749), (lutetium, isotope of mass 177), (used only for the radiolabelling of carrier molecules)
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

(EMEA/H/C/003785), (oritavancin), (treatment of complicated skin and soft tissue infections (cSSTI))

The Committee discussed the issues identified in this application The CHMP agreed to consult the SAG as well as the IDWP.

The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

(EMEA/H/C/002846), (tedizolid phosphate), (Treatment of complicated skin and soft tissue infections (cSSTI) in adults)
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

2.4. Update on on-going new applications for Centralised Procedures

(EMEA/H/C/002637), (balugrastim), (Treatment of chemotherapy-induced neutropenia)

List of Outstanding Issues adopted on 22.05.2014. List of Questions adopted on 19.09.2013.
The Committee agreed to the request from the applicant for an extension of clock stop to respond to the Day 180 List of Outstanding Issues adopted in May 2014,

(EMEA/H/C/002548), Orphan (afamelanotide), Applicant: Clinuvel (UK) Limited, (treatment of phototoxicity in adult patients with erythropoietic protoporphyria (EPP))
List of Outstanding Issues adopted 21.03.2013 and 23.01.2014. List of Questions adopted on 19.07.2012.
The Committee agreed to the request from the applicant for an extension of clock stop to submit responses to Day 180 List of Outstanding Issues adopted in January 2014.

(EMEA/H/C/002772) Orphan (dasiprotimut-t), Applicant: Biovest Europe Ltd, (treatment of non-Hodgkin's lymphoma (FL))
The Committee agreed to the request from the applicant for an extension of clock stop to respond to the Day 120 List of Questions adopted in April 2014.

(EMEA/H/C/002830), Orphan (mifepristone), Applicant: FGK Representative Service GmbH, (treatment of signs and symptoms of endogenous Cushing's syndrome in adults)
List of Questions adopted on 20.03.2014.
The Committee agreed to the request from the applicant for an extension of clock stop to respond to the Day 120 List of Questions.

(EMEA/H/C/002347), (perflubutane), (ultrasound imaging agent indicated for the detection of coronary artery disease (CAD))
Oral explanation was held in May 2014. List of Outstanding Issues adopted on 22.05.2014, 20.03.2014, 21.11.2013. List of Questions adopted on 21.02.2013.
The Committee adopted List of expert for SAG CVS.

(EMEA/H/C/002085) (tilmanocept), (used in the delineation and localisation of lymph nodes)
New active substance (Article 8(3) of Directive No 2001/83/EC)
Oral explanation held in March 2014. List of Outstanding Issues adopted on 22.03.2014, 19.12.2013 and 24.10.2013. List of Questions adopted in 30.05.2013.
The Committee adopted List of expert for SAG Oncology.

The Committee noted that there may be additional experts required. The final list of experts will be adopted via written procedure.

(EMEA/H/C/002807), (human fibrinogen / human thrombin), ((human plasma-derived fibrinogen and thrombin) is used as an adjunct to haemostasis)
List of Questions adopted on 22.03.2014.
The Committee agreed to the request from the applicant for an extension of clock stop to respond to the Day 120 List of Questions.

(EMEA/H/C/003728), (netupitant / palonosetron), (prevention of acute and delayed Chemotherapy-Induced Nausea and Vomiting (CINV) induced by highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).)
The Committee agreed to the request from the applicant for an extension of clock stop to respond to the Day 120 List of Questions adopted in May 2014.

(EMEA/H/C/003800), Orphan (ketoconazole), Applicant: Agenzia Industrie Difesa-Stabilimento Chimico Farmaceutico Militare, (treatment of Cushing's syndrome)
The Committee agreed to the request from the applicant for an extension of clock stop to respond to the Day 120 List of Questions adopted in April 2014.

2.5. Products in the Decision Making Phase

VANTOBRA (EMEA/H/C/002633), Orphan, (tobramycin), Applicant: PARI Pharma GmbH, (treatment of chronic pulmonary infection)
Hybrid application (Article 10(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 24.10.2013. List of Questions adopted on 21.02.2013. Opinion adopted in May 2014.
The Committee addressed the request from the European Commission for clarification in relation to the CHMP Opinion adopted for Vantobra at its May meeting.
The CHMP adopted a revised opinion by consensus together with the revised assessment report and similarity report.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

3. Extension of marketing authorisation according to Annex I of Reg. 1234/2008-Line extension procedures

3.1. Extension of marketing authorisation according to Annex I of Reg. 1234/2008; Opinions

Isentress (EMEA/H/C/000860/X/0044/G), (raltegravir), MAH: Merck Sharp & Dohme Limited, Rapporteur: Greg Markey, Co-Rapporteur: Pierre Demolis, PRAC Rapporteur: Julie Williams "Grouping of a line extension application to introduce a new pharmaceutical form (100 mg granules for oral suspension) and a type II variation to extend the indication to toddlers and infants from 4 weeks to less than 2 years of age. Consequently, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated and separate SmPC is introduced for the new pharmaceutical form. The Package Leaflet and Labelling are updated in accordance. In addition, minor updates are made to SmPC sections 5.1 and 6.1, Labelling and the PL. Furthermore, the product information is brought in line with the latest QRD version 9.3."
List of Outstanding Issues adopted on 25.04.2014. List of Questions adopted on 19.12.2013.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion by consensus, together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

Synagis (EMEA/H/C/000257/X/0095), (palivizumab), MAH: AbbVie Ltd., Rapporteur: Jens Heisterberg, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Line Michan, "Introduction of a new pharmaceutical form: 100 mg/ml Solution for injection presented in vials containing 0.5 ml and 1 ml."
List of Questions adopted on 20.02.2014.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion by consensus, together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

3.2. Extension of marketing authorisation according to Annex I of Reg. 1234/2008; Day 180 List of outstanding issues

No items

3.3. Extension of marketing authorisation according to Annex I of Reg. 1234/2008; Day 120 List of Questions

Ibandronic acid Accord (EMEA/H/C/002638/X/0006), (ibandronic acid), MAH: Accord Healthcare Limited, Generic, Rapporteur: Alar Irs, "To add a new strength/potency and a new pharmaceutical form 3 mg solution for injection."
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the List of Questions.

3.4. Update on on-going Extension application according to Annex I of Reg. 1234/2008

No items

4. TYPE II VARIATIONS - Extension of indication procedures

4.1. Opinions or Requests for Supplementary information - – Type II variation; Extension of indication

Avastin (EMEA/H/C/000582/II/0063), (bevacizumab), MAH: Roche Registration Ltd, Rapporteur: Jens Ersbøll, Co-Rapporteur: Ingunn Hagen Westgaard, PRAC Rapporteur: Doris Stenver, "Extension of Indication to include Avastin in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents. As a consequence of this new indication, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC have been updated. The Package Leaflet is updated accordingly."
Request for Supplementary Information adopted on 22.05.2014, 19.12.2013.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The summary of opinion was circulated for information.
The CHMP adopted the similarity assessment report.

ECALTA (EMEA/H/C/000788/II/0026), (anidulafungin), MAH: Pfizer Limited, Rapporteur: Pieter de Graeff, Co-Rapporteur: Jens Ersbøll, PRAC Rapporteur: Sabine Straus, "Following the CHMP assessment of efficacy and safety data of Ecalta in neutropenic patients with invasive candidiasis and non-neutropenic patients with Cancida deep tissue infection (MEA 014.3), update of sections 4.1, 4.4, 4.8 and 5.1 of the SmPC . The Package Leaflet is updated accordingly.
In addition the MAH proposes to take the opportunity of this variation to bring the SmPC in line with the QRD Annex I template version 9."
Request for Supplementary Information adopted on 20.03.2014.
The Committee discussed the issues identified in this application, relating to uncertainty with regard to fluconazole susceptibility for *Candida glabrata*.
The Committee adopted a Request for Supplementary Information with a specific timetable.

Eliquis (EMEA/H/C/002148/II/0014/G), (apixaban), MAH: Bristol-Myers Squibb / Pfizer EEIG, Rapporteur: Pieter de Graeff, Co-Rapporteur: Robert James Hemmings, PRAC Rapporteur: Sabine Straus, "Extension of indication for the treatment of deep vein thrombosis and pulmonary embolism and prevention of recurrent DVT and PE in adults. Consequently, the SmPC and Package leaflet are updated.
In addition, the MAH applied for a variation to add a new pack size of 28 film coated tablets for Eliquis 5mg strength (SmPC section 6.5).
The Package Leaflet and Labelling were proposed to be updated in accordance.

In addition, the patient alert card text currently approved has been reviewed in a parallel procedure and was amended to make it more concise. The amended text of the PAC is now inserted as part of the labelling in this application in order to harmonise with similar products, where the Patient Alert Card is part of the labelling."
Request for Supplementary Information adopted on 20.02.2014.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendation.
The summary of opinion was circulated for information.

Enbrel (EMEA/H/C/000262/II/0167), (etanercept), MAH: Pfizer Limited, Rapporteur: Robert James Hemmings, PRAC Rapporteur: Rafe Suvarna, "Extension of indication - treatment of adults with severe non-radiographic axial spondyloarthritis (nr-AxSpA"
Request for Supplementary Information adopted on 20.02.2014.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendation.
The summary of opinion was circulated for information.

Eylea (EMEA/H/C/002392/II/0009), (aflibercept), MAH: Bayer Pharma AG, Rapporteur: Pierre Demolis, Co-Rapporteur: Robert James Hemmings, PRAC Rapporteur: Isabelle Robin, "The MAH proposed the update of SmPC section 4.1 to add a new indication for treatment of adult patients with diabetic macular oedema. Consequential updates were proposed for SmPC sections 4.2, 4.4, 4.8, 5.1 and 5.2. SmPC section 4.8 was furthermore updated to introduce a single table of adverse drug reactions. The PL was updated accordingly."
Request for Supplementary Information adopted on 22.05.2014, 20.02.2014.
Request for 1-year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004).
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee agreed that a PAES on comparative efficacy of three different long-term treatment regimens will be included in Annex II.
The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendation.
The CHMP noted the letter of recommendation dated 24 June 2014.
The summary of opinion was circulated for information.
The CHMP adopted a negative opinion by consensus on the additional 1-year market protection as is was considered that the new therapeutic indication does not bring a significant clinical benefit in comparison with existing therapies.

Kalydeco (EMEA/H/C/002494/II/0009), Orphan, (ivacaftor), MAH: Vertex Pharmaceuticals (U.K.) Ltd., Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Melinda Sobor, PRAC Rapporteur: Miguel-Angel Macia, "Extension of Indication to include additional gating (class III) mutations in the CFTR gene: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N and S549R.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. Particularly, a new warning with regard to lack of clinically relevant improvement from treatment in patients with G970R mutation in the CFTR gene has been added to the product information. The Package Leaflet has been updated accordingly."
Request for Supplementary Information adopted on 25.04.2014, 23.01.2014.
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendation.
The summary of opinion was circulated for information.

Ozurdex (EMEA/H/C/001140/II/0015), (dexamethasone), MAH: Allergan Pharmaceuticals Ireland, Rapporteur: Greg Markey, Co-Rapporteur: Concepcion Prieto Yerro, PRAC Rapporteur: Julie Williams, "The MAH proposed the update of SmPC section 4.1 to add a new indication for treatment of adult patients with diabetic macular oedema. Consequential updates were proposed for SmPC sections 4.2, 4.4, 4.8, 5.1 and 5.2. The PL was updated accordingly. In addition, the MAH proposed to reduce and consolidate the current HCP leaflet, which is provided as tear off section after the PL.
The MAH also used this opportunity to implement QRD version 9.0."
Request for Supplementary Information adopted on 20.02.2014, 24.10.2013.
The Committee discussed the issues identified in this application, mainly relating to concerns on the clinical relevance of the effect size and some safety concern (including risk of development of cataract).
An Oral Explanation was held on Wednesday 25 June 2014 at 9.00. The applicant outlined the efficacy and safety data claiming that the benefit/risk being positive.
Following the Oral Explanation the Committee did not agree with the applicant's initially claimed indication but saw the possibility to further position the indication (possible restricted indication).
The Committee adopted a 3rd Request for Supplementary Information with a specific timetable.
See also I.3 Post-authorisation procedure Oral explanations.

Pandemrix (EMEA/H/C/000832/II/0069), (pandemic influenza vaccine (h1n1) (split virion, inactivated, adjuvanted) a/california/7/2009 (h1n1)v like strain (x-179a)), MAH: GlaxoSmithKline Biologicals, Rapporteur: Rafe Suvarna, PRAC Rapporteur: Julie Williams, "To revise the indication to reflect that Pandemrix should only be used for prophylaxis of influenza caused by A(H1N1)v 2009 if recommended seasonal influenza vaccine is not available and immunisation against A(H1N1)v 2009 is considered necessary, to update sections 4.4 and 4.8 of the SmPC to reflect the totality of the data on the risk of narcolepsy and to provide an updated benefit-risk assessment of Pandemrix, based on the data currently available to the MAH on H1N1 influenza disease burden, effectiveness and safety of Pandemrix and available epidemiology data on narcolepsy. The Package Leaflet is updated accordingly.
The MAH also took the opportunity to update the list of 'Obligation to conduct post-authorisation measures' in Annex II to remove the condition "Re-analysis of the dataset with adjustment for medically-attended respiratory infection/influenza-like illness" as the MAH will not be in a position to fulfil this request."
Request for Supplementary Information adopted on 20.03.2014.
In light with the CHMP chair being involved in the generation of data at the Swedish NCA, which was included in this variation, he decided to hand over the chairing of this discussion to the vice-chair.
The Swedish CHMP member Kristina Dunder questioned the benefit/risk of Pandemrix in any seasonal setting. She asked that her concern was included in the CHMP Minutes.

The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendation.
The summary of opinion was circulated for information.

Prezista (EMEA/H/C/000707/II/0063), (darunavir), MAH: Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Greg Markey, PRAC Rapporteur: Sabine Straus, "Update of section 4.1 of the SmPC for the 100mg/ml oral suspension and the 400mg, 800mg film-coated tablets with information on the use of darunavir with cobicistat as pharmacokinetic enhancer. Consequential changes have been introduced in the SmPC and the PL of all formulations. Update of the Annex II with a correction to the address of one of the manufacturers responsible for batch release. Update of the PL with the local representatives' contact information for France, Romania, Ireland and Cyprus."
Request for Supplementary Information adopted on 25.04.2014.
The Committee discussed the issues identified in this application, mainly related to an updated RMP and changes to the SmPC wording.
The Committee adopted a Request for Supplementary Information with a specific timetable.

Pyramax (EMEA/H/W/002319/II/0002), (pyronaridine / artesunate), MAH: Shin Poong Pharmaceutical Co., Ltd., Rapporteur: Joseph Emmerich, Co-Rapporteur: Johann Lodewijk Hillege, "x To amend SmPC section 4.1 (Therapeutic Indications) to remove restrictions on repeated course of treatment in any individual and use only in areas of low transmission with evidence of artesmisinin resistance, based on further clinical experience. Consequent changes in SmPC sections 4.2 (Posology), 4.4 (Special warnings and precautions), 4.8 (Undesirable effects) and the PL are also included.
A recommended change is made to SmPC Section 4.2 (Posology) in relation to dosing in mild to moderate renal impairment. A minor editorial adjustment is proposed to SmPC section 5.1 (Pharmacodynamic properties)."
The Committee discussed the issues identified in this application, mainly concerning clarification on the safety of repeated treatment in patients with sub-clinically and clinically relevant elevations of alanine aminotransferase (ALT).
The Committee adopted a Request for Supplementary Information with a specific timetable.

Relistor (EMEA/H/C/000870/II/0030), (methylnaltrexone bromide), MAH: TMC Pharma Services Ltd, Rapporteur: Harald Enzmann, Co-Rapporteur: Greg Markey, PRAC Rapporteur: Valerie Strassmann, "The MAH applied for an extension of the indication for the treatment of opioid induced constipation in adult non cancer pain patients. Consequently, the MAH proposed the update of sections 4.1, 4.2, 4.4 and 5.1 of the SmPC. The Package Leaflet was proposed to be updated in accordance."
The Committee discussed the issues identified in this application, mainly relating to insufficient data supporting the efficacy in the new patient population.
Following feedback from a drafting group to identify relevant questions, the Committee adopted a Request for Supplementary Information with a specific timetable that should also address the concerns raised about the 1-year market protection.

Rienso (EMEA/H/C/002215/II/0008), (ferumoxytol), MAH: Takeda Pharma A/S, Rapporteur: Harald Enzmann, Co-Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Martin Huber, "Extension of indication: all cause iron deficiency anaemia when oral therapy is ineffective or inappropriate or where there is a need for rapid iron repletion As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC were proposed to be updated. The Package Leaflet was proposed to be updated accordingly. The MAH took the opportunity to propose minor editorial changes to the SmPC and to propose the update of the Product Information in line with the latest version of the QRD template (9.0)"
Request for Supplementary Information adopted on 25.04.2014, 24.10.2013.
The Committee discussed the issues identified in this application, mainly concerning new data on serious hypersensitivity reactions. The CHMP noted that the PSUR of Rienso is under discussion at the PRAC.
The Committee adopted a Request for Supplementary Information with a specific timetable.

Stivarga (EMEA/H/C/002573/II/0001) (regorafenib), MAH: Bayer Pharma AG, Rapporteur: Pieter de Graeff, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Sabine Straus, "Extension of indication in the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.3 of the SmPC have been updated. The Package Leaflet has been updated accordingly. The list of local representatives was also updated in the package leaflet."
Request for Supplementary information adopted on 22.05.2014, 19.12.2013.
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004).
The Committee confirmed that all issues previously identified in this application had been resolved.
The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendation.
The summary of opinion was circulated for information.
The CHMP adopted a positive opinion by consensus on the 1-year market protection as it was considered that the new therapeutic indication brings a significant clinical benefit in comparison with existing therapies.

4.2. Update on on-going Type II variation - Extension of indications

Tracleer (EMEA/H/C/000401/II/0066), (bosentan), MAH: Actelion Registration Ltd., Rapporteur: Pierre Demolis, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Evelyne Falip, "Extension of indication to include treatment of symptomatic pulmonary arterial hypertension in paediatric patients aged from 3 months to 18 years."
The CHMP adopted the updated similarity assessment report for Tracleer.

Tasigna (EMEA/H/C/000798/II/0061), Orphan, (nilotinib), MAH: Novartis Europharm Ltd, Rapporteur: Jens Ersbøll, Co-Rapporteur: Harald Enzmann, PRAC Rapporteur: Doris Stenver, "Extension of indication of Tasigna 200mg hard capsules for the treatment of adult patients with Philadelphia chromosome positive CML in the chronic phase who have not achieved a molecular response greater than or equal to a 4.5-log reduction with imatinib treatment".
Request for Supplementary Information adopted on 20.03.2014, 24.10.2013.

The Committee noted the letter from the MAH dated 21 May 2014 informing of the decision to withdraw this procedure.

5. ANCILLARY MEDICINAL SUBSTANCES IN MEDICAL DEVICES

5.1. Opinions / Day 180 List of outstanding issues / Day 120 List of Questions

(EMEA/H/D/002769), (thrombin), (is indicated in surgical procedures)
List of Outstanding Issues adopted on 25.04.2014. List of Questions adopted in 19.09.2013.
The Committee was reminded of the status of this application and its remaining outstanding issues,
The Committee adopted the 2nd List of Outstanding Issues with a specific timetable.
The Committee adopted the BWP report.

6. RE-EXAMINATION PROCEDURE (NEW APPLICATIONS) UNDER ARTICLE 9(2) OF REGULATION No 726/2004

No items

7. RE-EXAMINATION PROCEDURE (TYPE II VARIATIONS) UNDER ARTICLE 6(9) OF COMMISSION REGULATION EC NO 1085/2003

Avastin (EMEA/H/C/000582/II/0059), (bevacizumab), MAH: Roche Registration Ltd,
Rapporteur: Jens Ersbøll, Co-Rapporteur: Ingunn Hagen Westgaard, PRAC Rapporteur: Doris Stenver,
"Update of section 4.1 of the SmPC in order to extend the indication of Avastin in combination with radiotherapy and temozolomide for the treatment of adult patients with newly diagnosed glioblastoma."
Opinion adopted on 22.05.2014.
The CHMP noted the letter from the applicant dated 5 June 2014 requesting re-examination of the Opinion adopted in May 2014.
The CHMP appointed a re-examination Rapporteur and a re-examination Co-Rapporteur.
PRAC re-examination Rapporteurs were also appointed.

8. WITHDRAWAL OF APPLICATION

(EMEA/H/C/003720), (faldaprevir), (treatment of chronic genotype-1 hepatitis C virus (HCV) infection)
List of Questions adopted on 20.03.2014.
The CHMP noted the letter from the applicant dated 10 June 2014 informing of the decision to withdraw the Marketing Authorisation Application.

9. PROCEDURE UNDER ARTICLE 83(1) OF REGULATION (EC) 726/2004 (COMPASSIONATE USE)

No items

10. PRE-SUBMISSION ISSUES

(H0003794) (asfotase alfa), (long-term enzyme replacement therapy in patients with hypophosphatasia with either perinatale/infantile onset (0-6 months at onset of symptoms) or juvenile onset (6 months to 18 years at onset of symptoms))
The CHMP agreed to the accelerated assessment request and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

11. POST-AUTHORISATION ISSUES

Procoralan (EMEA/H/C/000597/II/0030), (ivabradine), MAH: Les Laboratoires Servier, Rapporteur: Pieter de Graeff, "C.I.13 Submission of the report of the clinical study CL3-16257-068." Request for Supplementary Information adopted on 25.04.2014.The Committee discussed the issues identified in this application, mainly relating to the SmPC wording. Furthermore the Committee was updated on the ongoing Article 20 procedure on Procorolan/Corlentor.
The CHMP agreed suspending the finalisation of these variation procedures until the ongoing Article 20 procedure on Procorolan/Corlentor (Ivabradine Art. 20 EMEA/H/A-20/1404) has been finalised, as the outcome of this referral procedure may affect the benefit/risk balance.
The Committee adopted a 2nd Request for Supplementary Information with a specific timetable.

Corlentor (EMEA/H/C/000598/II/0029), (ivabradine), MAH: Les Laboratoires Servier, Rapporteur: Pieter de Graeff, "C.I.13 Submission of the report of the clinical study CL3-16257-068 " Request for Supplementary Information adopted on 25.04.2014.See Procoralan II/30

WS0492
M-M-RVAXPRO-EMEA/H/C/000604/WS0492/0059
Proquad-EMEA/H/C/000622/WS0492/0077
(measles, mumps and rubella vaccine (live)measles, mumps, rubella and varicella vaccine (live)), MAH: Sanofi Pasteur MSD SNC, Rapporteur: Jan Mueller-Berghaus, Procedure "To update section 4.8 of the SmPC to include acute disseminated encephalomyelitis (ADEM) in section 4.8 of the SmPC based on a review of reports of cases of encephalopathy consistent with ADEM for measles, mumps and rubella virus vaccine live (M-M-R II / M-M-RVaxpro) and measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live (ProQuad).
Request for Supplementary Information adopted on 20.03.2014.
The CHMP was updated on the remaining issues, mainly concerning the proposed inclusion of ADEM in section 4.8 of the SmPC.
The Committee adopted a 2nd Request for Supplementary Information with a specific timetable.

12. REFERRAL PROCEDURES

12.1. Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004

No items

12.2. Requests for CHMP Opinion under Article 5(3) and 57 (1)p of Regulation (EC) No 726/2004

No items

12.3. Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004

No items

12.4. Disagreement between Member States on application for medicinal product (Potential serious risk to Public Health) –under Article 29(4) of 2001/83/EC

Seasonique film coated tablets (EMEA/H/A-29(4)/1392) (levonogestrel 150 µg and ethinylestradiol 30 µg / 10 µg), MAH: Teva Pharma B.V (NL), Rapporteur: Joseph Emmerich, Co-Rapporteur: Martina Weise, RMS: FR, CMS: AT, BE, DE, IT, PL, RO, SI ,SK, Procedure number: FR/H/0516/001/DC,
Article 29(4) triggered due to disagreement with regard to the demonstration of contraceptive effectiveness and treatment compliance.
List of Questions adopted on 20 February 2014.
The Committee was reminded of previous discussions. The members discussed the validity of the Pearl Index further to consulting the Biostatistics Working Party on the validity of a confidence interval of the Peal Index calculated using the Poisson method versus the Bootstrap method. In addition the members discussed the possibility of extrapolating known efficacy of this fixed dose combination in standard cycles to this extended regimen use. Furthermore available data on the ovulation inhibition and bleeding pattern were considered. Some members expressed concern that the contraceptive efficacy has not been sufficiently demonstrated.
The CHMP adopted a positive opinion by majority (19 out of 33 votes) together with the CHMP assessment report.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The divergent position (Agnes Gyurasics, Alar Irs, Bruno Sepodes, Daniela Melchiorri, David Lyons, Greg Markey, Harald Enzmann, Jan Mueller-Berghaus, Jens Heisterberg, Mila Vlaskovska, Outi Maki-Ikola, Piotr Fiedor, Robert Hemmings, Radka Montoniova) was appended to the opinion.
The question-and-answer document was circulated for information.

12.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

Sandostatin LAR (EMEA/H/A-30/1355) (octreotide acetate) Novartis Pharma AG group of companies and associated companies. Rapporteur: Agnes Gyurasics, Co-Rapporteur: Robert James Hemmings,
List of Outstanding Issues adopted in November 2014. List of Questions adopted in May 2013.
The CHMP agreed that all outstanding issues were considered resolved.
The CHMP adopted an opinion by consensus, recommending the variation to the terms of the Marketing Authorisations.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The question-and-answer document was circulated for information.

Sandostatin (EMA/H/A-30/1354) (octreotide acetate) Novartis Pharma AG Group of companies and associated companies. Rapporteur: Agnes Gyurasics, Co-Rapporteur: Robert James Hemmings,
List of Outstanding Issues adopted in November 2014. List of Questions adopted in May 2013.
The CHMP agreed that all outstanding issues were considered resolved.
The CHMP adopted an opinion by consensus, recommending the variation to the terms of the Marketing Authorisations.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The question-and-answer document was circulated for information.

Haldol and associated names (EMEA/H/A-30/1393) (haloperidol), Janssen-Cilag Group of companies and associated companies
Rapporteur: Martina Weise, Co-Rapporteur: Ivana Mikacic,
The Committee noted the letter from the European Commission dated 18 June 2014 informing of start of the procedure in June 2014. The CHMP noted the proposals for a harmonised product information.
The Committee adopted the CHMP List of Questions with a specific timetable:
Start of procedure: 26.06.2014; Responses to list of questions: 29.09.2014; Restart of the procedure: 21.10. 2014; Assessment report: 05.11. 2014; Comments from CHMP: 10.11.2014; List of outstanding issues or CHMP opinion: November 2014 CHMP

Haldol decanoate and associated names (EMEA/H/A-30/1405) (haloperidol) Janssen-Cilag Group of companies and associated companies
Rapporteur: Martina Weise, Co-Rapporteur: Ivana Mikacic,
The Committee noted the letter from the European Commission dated 18 June 2014 informing of start of the procedure in June 2014. The CHMP noted the proposals for a harmonised product information.
The Committee adopted the CHMP List of Questions with a specific timetable:
Start of procedure: 26.06.2014; Responses to list of questions: 29.09.2014; Restart of the procedure: 21.10. 2014; Assessment report: 05.11. 2014; Comments from CHMP: 10.11.2014; List of outstanding issues or CHMP opinion: November 2014 CHMP

12.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

Gadolinium containing contrast agents, Gd-Cas (EMEA/H/A-31/1097)
Rapporteur: Rafe Suvarna, Co-Rapporteur: Pieter de Graeff,
The CHMP adopted the FUM related to the 3rd annual cumulative safety reviews on nephrogenic systemic fibrosis (NSF): Omniscan (GE HealthCare) fifth monthly update and interim analysis report submission as requested by CHMP in November 2013 and assessment report.

12.7. Re-examination procedure under Article 32(4) of Directive 2001/83/EC

No items

12.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

12.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003)

No items

12.10. Procedure under Article 29 Regulation (EC) 1901/2006

No items

12.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008)

No items

13. PHARMACOVIGILANCE ISSUES

Summary of recommendations and advice of PRAC meeting held on 10-13 June 2014: **for information**	The Committee noted the report. The members noted the Summary of recommendations and advices of the PRAC meeting.
List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for June 2014: **for adoption**	The EURD list was adopted.
Early Notification System: June 2014 Early Notification System on Envisaged CHMP Recommendations for Regulatory Action (based on Identified Safety Concerns) Accompanied by Communication to the General Public: **for information**	See individual items

14. INSPECTIONS

14.1. GMP Inspections

Request for GMP Inspections: **for adoption**	*Disclosure of information relating to GMP inspections will not be published as undermining the purpose of such inspections.*

14.2. GCP Inspections

Request for GCP Inspections: **for adoption**	*Disclosure of information relating to GCP inspections will not be published as undermining the purpose of such inspections.*

14.3. Pharmacovigilance Inspections

	Disclosure of information relating to Pharmacovigilance inspections will not be published as undermining the purpose of such inspections.

14.4. GLP Inspections

Request for GLP Inspections: **for adoption**	*Disclosure of information relating to GLP inspections will not be published as undermining the purpose of such inspections.*

15. INNOVATION TASK FORCE

15.1. Minutes of ITF: For information

Minutes from the May ITF Plenary held on 23 May 2014: **For information**	The minutes were noted by the CHMP.

15.2. Briefing meetings (Innovation Task Force)

Disclosure of information relating to briefing meetings taking place with applicants cannot be released at present time as deemed containing commercially confidential information

15.3. Eligibility to EMA scientific services

15.4. Requests for CHMP Opinion under Article 57 (1)P of Regulation (EC) NO 726/2004

Request from EDQM for EMA scientific opinion under Art. 57 (1)P of Regulation (EC) No 726/2004 Appointment of CHMP Co-ordinator: **For discussion**	The CHMP noted the request from the EDQM.

15.5. Nanomedicines activities

16. SCIENTIFIC ADVICE WORKING PARTY (SAWP)

Report from the SAWP meeting held on 2-5 June 2014. Table of conclusions: **for information**	The CHMP noted the report.
Scientific advice letters:	*Disclosure of information relating to scientific advice letters cannot be released at present time as deemed containing commercially confidential information.*

17. SATELLITE GROUPS / OTHER COMMITTEES

17.1. Coordination Group for Mutual Recognition and Decentralised Procedures

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 23-25 June 2014: **for information**	The CHMP noted the report.

18. OTHER COMMITTEES

18.1. Committee for Medicinal Products for Veterinary Use (CVMP)

Update from CVMP on the evaluation of the potential risk for the consumer resulting from the use of lidocaine in food producing species: **For information**	Article 30(3) procedure started at CVMP in January 2013. The CHMP noted the on-going assessment of the potential risk for the consumer resulting from the use of lidocaine in food producing species.

18.2. Committee for Orphan Medicinal Products (COMP)

Press release of the COMP meeting held on 10-12 June 2014: **for information**	To be sent in the Post-mail.

18.3. Committee for Herbal Medicinal Products (HMPC)

HMPC request to PRAC and SWP on toxicological assessment of pulegone/menthofuran and consequences for medicinal products containing menthae piperitae aetheroleum: **For information**	The CHMP noted the request from the HMPC to the SWP.
Updated Request from the HMPC to the SWP on conclusions of a toxicological assessment of estragole and alkenylbenzenes: **For information**	Follow up from March 2014. The CHMP noted the updated request.

18.4. Paediatric Committee (PDCO)

PIPs reaching D30 at June 2014 PDCO: **for information**	To be sent in the Post-mail.
Report from the PDCO meeting held on 18-20 June 2014: **for information**	The CHMP noted the report.
Request from the PDCO for the input regarding the draft Paediatric Investigation Plan for DTaP-containing combination vaccine: **for discussion**	Postponed
PDCO questions to CHMP dated 2 April 2014 on (R)-2-[3-({Benzoxazol-2-yl[3-(4-methoxyphenoxy)propyl]amino}methyl)phenoxy] butanoic acid (K-877) (EMEA-001573-PIP01-13): **For adoption**	The CHMP discussed the draft response to the PDCO and concluded to consult the Cardiovascular Working Party and to adopt the final response via written procedure after the Plenary.

18.5. Committee for Advanced Therapies (CAT)

Table of Decisions of CAT meeting held on 19-20 June 2014: **for information**	The CHMP noted the Table of Decision.

19. INVENTED NAME ISSUES

Table of Decisions of the NRG meeting held on 15 May 2014: **For adoption**	The CHMP noted the Table of Decision.

20. ANY OTHER BUSINESS

Election of QWP Chair in June 2014: **For adoption**	Jean Louis Robert was re-elected as QWP chair
CHMP/CVMP Quality Working Party survey regarding in-use shelf-life of reconstituted/ compounded parenteral products: **For adoption**	The CHMP noted the proposal for a survey. An update will be presented at the July Plenary following further discussions.
Presentation on move to 30 Churchill Place	The members were informed about the new access-cards and their use in the new building. Furthermore details were given on the technical set up of the Plenary, especially the use of a virtual platform (Adobe Connect) allowing national experts in their agencies to follow the slides presented during the meeting. A site visit of the new building will be organised during the July CHMP meeting with the first CHMP Plenary taking place in the new building in September 2014.
Follow up action plan Quality of Opinions	The CHMP discussed the follow up action plan on Quality of Opinions
Action Plan from the CHMP informal meeting under the Greek presidency held in Uppsala on 26 – 28 May 2014: **For adoption**	The CHMP agreed the action plan. It was noted that the presentations and minutes are available to all members.
Feedback from informal CHMP meeting held in Uppsala on 26 – 28 May 2014 on the pilot phase to involve patients at CHMP oral explanations: **For discussion** Pilot phase to involve patients in benefit/risk discussions at CHMP meetings: **For adoption**	The CHMP noted the proposal on a pilot phase to involve patients in benefit/risk discussions at CHMP meetings. Members were informed that a public communication will be prepared once the pilot started.
Q&A on excipients Gluten (EMA/CHMP/704219/2013): **For adoption for 3-month public consultation**	Postponed to July 2014.
Overview of comments received on 'Guideline on stability testing for applications for variations to a marketing authorisation' (EMA/CHMP/CVMP/QWP/441071/2011): **For information**	The CHMP noted the updated Overview of comments received on 'Guideline on stability testing for applications for variations to a marketing authorisation'

Call for assessor's interest to attend the Regulatory session on the 'latest developments in Alzheimer's disease' during the ECNP congress on Monday 20 October 2014: **For information**	This open session was organised in collaboration between ECNP and EMA/CNSWP and will include speakers from EMA, industry and academia: http://www.ecnp-congress.eu/Highlights/Regulatory%20update%20session.aspx The registration for this session is free. The CNSWP members/observers have been informed directly in parallel.
Questions & answers on practical implementation of Article 20 Pharmacovigilance Procedure, revised version: **For information**	Postponed to July
August CHMP plenary to be replaced by CHMP written procedure: **For adoption** Timetable for August 2014 written procedure: **For adoption**	The CHMP adopted the timetable for the August 2014 written procedure replacing a face-to-face meeting
CHMP Work Plan 2015	The Committee discussed the status of the topics on the current CHMP work plan and highlighted topics which they would like to elaborate on in 2015. The CHMP agreed to discuss the Work Plan quarterly at the ORGAM meeting to follow the status of the topics.
Mandate, objectives and rules of procedure for a new Ethics Advisory Group (EAG): **For discussion**	The CHMP noted the Mandate, objectives and rules of procedure for a new EAG.
Update on Benefit-Risk methodology project: Effects Table: **for information**	The CHMP noted the outcome of the pilot phase on 12 products as well as the feedback questionnaire completed by the involved assessor teams. The pilot will be finalised in September 2014. It was proposed to update the PRAC on this pilot project.
Consultation on proposed process improvements for initial MAA, PIQ/QRD, Linguistic Accuracy, Referral and Scientific Advice process.	The CHMP was informed about the planned consultations on proposed process improvements including the timelines for the initiatives. The nominations received by the management board for the initial MAA process will be shared with the Com

Quarterly report of planned MAAs with already appointed Rapporteurs: **For information**	The members noted the quarterly report.

1. **List of participants:** *including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 23-26 June 2014 meeting.*

CHMP Chair	*Country*	*Outcome restriction following evaluation of e-DoI for the meeting*	*Topics on the current Committee Agenda for which restriction applies* *Product / substance*
Tomas Salmonson	Sweden	Full involvement	

CHMP Member	*Country*	*Outcome restriction following evaluation of e-DoI for the meeting*	*Topics on the current Committee Agenda for which restriction applies* *Product / substance*
Andrea Laslop	Austria	Full involvement	
Daniel Brasseur	Belgium	Full involvement	
Mila Vlaskovska	Bulgaria	Full involvement	
Ivana Mikačić	Croatia	No participation in final deliberations and voting on:	(EMEA/H/C/003785), (oritavancin)
			(EMEA/H/C/002846), (tedizolid phosphate)
Panayiotis Triantafyllis	Cyprus	Full involvement	
Ondřej Slanař	Czech Republic	No participation in discussions, final deliberations and voting on:	(EMEA/H/C/002819), (darunavir / cobicistat)
			(EMEA/H/C/002754), (dolutegravir / abacavir / lamivudine)
			(EMEA/H/C/002647), (insulin degludec / liraglutide)
			(EMEA/H/C/002835) (insulin glargine)
			(EMEA/H/C/002825), (dulaglutide)
Jens Heisterberg	Denmark	Full involvement	

CHMP Member	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product / substance
Alar Irs	Estonia	Full involvement	
Outi Mäki-Ikola	Finland	No participation in final deliberations and voting on:	(EMEA/H/C/002705), (mixture of polynuclear iron(iii)-oxyhydroxide, sucrose and starches)
			Enbrel (EMEA/H/C/000262/II/0167), (etanercept)
			Rienso (EMEA/H/C/002215/II/0008), (ferumoxytol)
			Procoralan (EMEA/H/C/000597/II/0030), (ivabradine)
			Corlentor (EMEA/H/C/000598/II/0029), (ivabradine)
Pierre Demolis	France	Full involvement	
Harald Enzmann	Germany	Full involvement	
Dimitrios Kouvelas	Greece	Full involvement	
Agnes Gyurasics	Hungary	Full involvement	
Kolbeinn Gudmundsson	Iceland	Full involvement	
David Lyons	Ireland	Full involvement	
Romaldas Mačiulaitis	Lithuania	Full involvement	
Jacqueline Genoux-Hames	Luxembourg	Full involvement	
John Joseph Borg	Malta	Full involvement	
Pieter de Graeff	Netherlands	Full involvement	
Karsten Bruins Slot	Norway	Full involvement	
Piotr Fiedor	Poland	Full involvement	
Bruno Sepodes	Portugal	Full involvement	
Nela Vilceanu	Romania	Full involvement	
Jan Mazag	Slovakia	Full involvement	

CHMP Member	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product / substance
Concepcion Prieto Yerro	Spain	Full involvement	
Kristina Dunder	Sweden	Full involvement	
Greg Markey	United Kingdom	Full involvement	
Robert James Hemmings	Co-opted	Full involvement	
Sol Ruiz	Co-opted	Full involvement	
Jean-Louis Robert	Co-opted	Full involvement	
Jan Mueller-Berghaus	Co-opted	Full involvement	
Hubert Leufkens	Co-opted	Full involvement	

CHMP Alternate	*Country*	*Outcome restriction following evaluation of e-DoI for the meeting*	*Topics on the current Committee Agenda for which restriction applies* *Product / substance*
Milena Stain	Austria	Full involvement	
Bart Van der Schueren	Belgium	Full involvement	
Ana Dugonjić	Croatia	Full involvement	
Radka Montoniová	Czech Republic	Full involvement	
Jens Ersbøll	Denmark	Full involvement	
Martina Weise	Germany	Full involvement	
George Aislaitner	Greece	Full involvement	
Melinda Sobor	Hungary	Full involvement	
Patrick Salmon	Ireland	Full involvement	
Daniela Melchiorri	Italy	Full involvement	*Replacing CHMP member*
Natalja Karpova	Latvia	Full involvement	*Replacing CHMP member*
Johann Lodewijk Hillege	Netherlands	Full involvement	
Ingunn Hagen Westgaard	Norway	Full involvement	
Aldona Paluchowska	Poland	Full involvement	
Dinah Duarte	Portugal	Full involvement	
Jana Klimasová	Slovakia	Full involvement	
Nevenka Tršinar	Slovenia	Full involvement	*Replacing CHMP member*
Arantxa Sancho-Lopez	Spain	Full involvement	
Filip Josephson	Sweden	Full involvement	

CHMP Alternate	*Country*	*Outcome restriction following evaluation of e-DoI for the meeting*	*Topics on the current Committee Agenda for which restriction applies* *Product /* *substance*
Rafe Suvarna	United Kingdom	Full involvement	

EUROPEAN COMMISSION	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product / substance
	European Commission	Full involvement	

CHMP Expert	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product / substance
* Experts were only evaluated against the product they have been invited to talk about.			
Valerie Lescrainier	Belgium	Full involvement	
Theis Moeslund Jensen	Denmark	Full involvement	
Ljiljana Milosevic-Kapetanovic	France	Full involvement	
Lotfi Boudali	France	Full involvement	
Pierre Mutuon	France	Full involvement	
Alexandre Moreau	France	Full involvement	
Ingrid Chau	France	Full involvement	
Nathalie Morgensztejn	France	Full involvement	
Vincent Gazin	France	Full involvement	
Sabine Mayrhofer	Germany	Full involvement	
Ralf Meyer	Germany	Full involvement	

CHMP Expert	*Country*	*Outcome restriction following evaluation of e-DoI for the meeting*	*Topics on the current Committee Agenda for which restriction applies* *Product / substance*
Eirini Apostolidou	Greece	Full involvement	
Mariëtte Kooper	Netherlands	Full involvement	
Shirley Hopper	United Kingdom	Full involvement	
Elspeth Gray	United Kingdom	Full involvement	
David Silverman	United Kingdom	Full involvement	
Mair Powell	United Kingdom	Full involvement	
Jonathan Sisson	United Kingdom	Full involvement	

CHMP Expert by phone	*Country*	*Outcome restriction following evaluation of e-DoI for the meeting*	*Topics on the current Committee Agenda for which restriction applies* *Product / substance*
* Experts were only evaluated against the product they have been invited to talk about.			
Antonio Gómez-Outes	Spain	Full involvement	
Teresa Dannert Alsasua	Spain	Full involvement	
Nuria García-Escribano	Spain	Full involvement	
Jan Willem Van der Laan	Netherlands	Full involvement	
Jan Schellens	Netherlands	Full involvement	
Norbert Benda	Germany	Full involvement	
Emmanouil Zouridakis	United Kingdom	Full involvement	
Catherine Tregunno	United Kingdom	Full involvement	
Antonio Jose Almeida	Portugal	Full involvement	
Hannu Järveläinen	Finland	Full involvement	
Elmer Schabel	Germany	Full involvement	
Paula Salmikangas	Finland	Full involvement	

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 1)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 2 and 3) or referral procedures (section 12) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

New applications *(section 2)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 2.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether a marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 2.2 (**Day 180 List of outstanding issues**) and 2.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 2.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 2.5, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 3)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 4)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 3. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 5)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 6)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section 7)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 8)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 9)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 10)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 11)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 12)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 13)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 14)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 15)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 16)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 17)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 18)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.